ClinicalTrials.gg
Not yet recruitingNCT06057194LETERCORUpdated Sep 28, 2023

Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

A Phase 2 interventional study of Letermovir 240 mg Oral Tablet in Infections, Cytomegalovirus, sponsored by Maimónides Biomedical Research Institute of Córdoba. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Maimónides Biomedical Research Institute of Córdoba · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.

Planned enrollment
6th of 17
90 · median 80
Started
2023
with 3 others
Phase 2
4 of 17
1 open now
Registered
11th of 17
by date
Lead sponsor
1 of 17
Maimónides Biomedical Research Institute of Córdoba

Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 6th largest by planned enrollment, is one of 4 that started in 2023, is one of 4 in phase 2, and was the 11th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About letermovir

letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letermovir in Cytomegalovirus Infections, or all of them as a file.
02

Study summary

The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease."

03

Conditions studied

  • Infections, Cytomegalovirus

Keywords

  • Lung transplant
  • CMV prophylaxis
  • Cytomegalovirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (prospective cohort):

  • Adults over 18 years old
  • Lung transplant recipients (D+/R-) pre-transplant.
  • Having an undetectable CMV polymerase chain reaction assay (PCR) within the 96 hours prior to the start of letermovir prophylaxis.
  • Patients who have provided written .

Exclusion Criteria (prospective cohort):

  • -infected patients.
  • Patients with multivisceral transplant.
  • Patients unable to comply with the follow-up protocol.
  • Receiving a different antiviral prophylaxis other than ganciclovir prior to letermovir prophylaxis.
  • Patients with concurrent renal and hepatic insufficiency.

Inclusion Criteria (retrospective cohort):

  • Adults over 18 years old. Lung transplant recipients (D+/R-) pre-transplant.
  • Patients treated with Valganciclovir prophylaxis for 12 months.
  • Patients transplanted within 2 years prior to the start of the study.
  • Patients with a complete 13-month follow-up and comparable data to the prospective cohort to evaluate the study's primary variables.

Exclusion Criteria (retrospective cohort):

  • HIV-infected patients.
  • Patients with multivisceral transplant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Letermovir (prospective cohort)

    2 tablets of 240 milligrams (mg) Letermovir orally once daily. during 12 months

    Drug: Letermovir 240 mg Oral Tablet

  • No intervention
    Valganciclovir (retrospective cohort)

    Retrospective cohort, of patients treated with Valganciclovir during 12 months

Interventions

  • DrugLetermovirStudies of LetermovirLetermovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation.

06

What researchers measure

Primary outcomes

  1. Incidence of CMV disease/replication

    CMV replication: The term 'replication' can be used to indicate evidence of multiplication and is sometimes used interchangeably with CMV infection CMV disease: It is defined as symptomatic replication or invasive disease of organs or tissues that requires treatment at the investigator's discretion."

    Time frame: During 12 months after initiation of prophylaxis

Secondary outcomes

  1. Antiviral prophylaxis received:

    Doses administered of Letermovir or Valganciclovir

    Time frame: During 12 months after initiation of prophylaxis

  2. Dose of non anti-viral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins)

    Drug Dose (mg/hour)

    Time frame: During 12 months after initiation of prophylaxis

  3. Administration route of non-antiviral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins)

    Drug Administration Route

    Time frame: During 12 months after initiation of prophylaxis

  4. Duration of treatment of non-antiviral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins)

    Drug treatment duration (days)

    Time frame: During 12 months after initiation of prophylaxis

  5. Discontinuation of non-antiviral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins)

    Drug Reason for Discontinuation

    Time frame: During 12 months after initiation of prophylaxis

  6. Reduction of the antiviral dose related to CMV antiviral toxicity

    Number of events of reduction

    Time frame: During 12 months after initiation of prophylaxis

  7. Substitution of letermovir by intravenous ganciclovir or foscarnet IV, related to CMV antiviral toxicity

    Number of substitutions

    Time frame: During 12 months after initiation of prophylaxis

  8. Dose changes of immunosuppressive therapy related to CMV antiviral toxicity

    Number of changes

    Time frame: During 12 months after initiation of prophylaxis

  9. Changes of immunosuppressive therapy related to CMV antiviral toxicity

    Number of changes

    Time frame: During 12 months after initiation of prophylaxis

  10. Use of granulocyte colony-stimulating factors (G-CSF).

    Number of events (use)

    Time frame: During 12 months after initiation of prophylaxis

  11. Incidence of leucopenia

    Incidence of leucopenia. (leucopenia will be considered if the total leukocyte count is less than 3,000/mL)

    Time frame: During 12 months after initiation of prophylaxis

  12. Incidence of neutropenia

    Incidence of leucopenia. (neutropenia will be considered if the total neutrophil count is less than 1,000/mL)

    Time frame: During 12 months after initiation of prophylaxis

  13. Hospital readmission associated with CMV complication

    Number of events

    Time frame: During 12 months after initiation of prophylaxis

  14. Incidence of viral, bacterial, or opportunistic fungal infections during the study follow-up period.

    Number of events

    Time frame: During 12 months after initiation of prophylaxis

  15. Incidence of renal toxicity directly related to CMV antivirals.

    Number of events

    Time frame: During 12 months after initiation of prophylaxis

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2023; primary completion for Apr 2027, 42 months later.

Of 29 phase 2 interventional studies under Cytomegalovirus Infections, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 62. This study's planned 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2023
First posted
Sep 28, 2023
StartEst.
Oct 2023
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06057194
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Collaborators
MERCK SHARP & DOHME DE ESPAÑA S.A.
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Oct 2023 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 28, 2023

Study contacts

Jose C Garrido Gracia, Ph.D
Contact
josecarlos.garrido@imibic.org
+34677906567
Julián C De la Torre Cisneros, MD
principal investigator · Hospital Universitario Reina Sofia de Cordoba

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion